


Article

Isotope Tracing Untargeted Metabolomics Reveals Macrophage Polarization-State-Specific Metabolic Coordination across Intracellular Compartments



Patrycja Puchalska, Xiaojing Huang, Shannon E. Martin, Xianlin Han, Gary J. Patti, Peter A. Crawford

crawforp@umn.edu

HIGHLIGHTS

Classically and alternatively polarized macrophages leverage hexosamine biosynthesis

Multiple carbon sources support hexosamine and itaconate biosynthesis

Intracellular metabolic compartmentation varies with macrophage polarization

Itaconate is imported into alternatively polarized macrophages

Puchalska et al., iScience 9, 298–313
November 30, 2018 © 2018
The Authors.
<https://doi.org/10.1016/j.isci.2018.10.029>

Article

Isotope Tracing Untargeted Metabolomics Reveals Macrophage Polarization-State-Specific Metabolic Coordination across Intracellular Compartments

Patrycja Puchalska,^{1,2,8} Xiaojing Huang,^{2,3,4,8} Shannon E. Martin,^{2,5} Xianlin Han,^{2,6} Gary J. Patti,³ and Peter A. Crawford^{1,2,7,9,*}

SUMMARY

We apply stable isotope tracing, mass-spectrometry-based untargeted metabolomics, to reveal the biochemical space labeled by ¹³C-substrates in bone-marrow-derived macrophages. At the pathway level, classically (lipopolysaccharide [LPS]-polarized, M1) and alternatively (interleukin [IL]-4-polarized, M2) polarized macrophages were ¹³C-labeled with surprising concordance. Total pools of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), an intermediate in the hexosamine biosynthetic pathway, were equally abundant in LPS- and IL-4-polarized macrophages. Informatic scrutiny of ¹³C-isotopologues revealed that LPS-polarized macrophages leverage the pentose phosphate pathway to generate UDP-GlcNAc, whereas IL-4-polarized macrophages rely on intact glucose and mitochondrial metabolism of glucose carbon. Labeling from [¹³C]glucose is competed by unlabeled fatty acids and acetoacetate, underscoring the broad roles for substrate metabolism beyond energy conversion. Finally, the LPS-polarized macrophage metabolite itaconate is imported into IL-4-polarized macrophages, in which it reprograms [¹³C]glucose metabolism. Thus, use of fully unsupervised isotope tracing metabolomics in macrophages reveals polarization-state-specific metabolic pathway connectivity, substrate competition, and metabolite allocation among cellular compartments.

INTRODUCTION

Macrophages participate in both the innate and adaptive immune systems to maintain tissue homeostasis, monitor and modulate the microenvironment via surface receptors, and coordinate other immune cell functions via cytokine signaling (Geeraerts et al., 2017; Kim et al., 2016). Although an oversimplification of the temporal plasticity and diversity of macrophage function, the M1/M2 paradigm of macrophage polarization characterizes different macrophage populations. Classically polarized (lipopolysaccharide [LPS]-polarized, M1) macrophages are triggered by toll-like receptor ligands, e.g., bacterial LPS, to induce a cascade promoting proinflammatory gene expression (e.g., *Il1b*, *Il6*, *Tnfa*, *Nos2*) (Tur et al., 2017). Alternatively polarized (interleukin [IL]-4-polarized, M2) macrophages are triggered by IL-4 or IL-13 and express arginase 1 (*Arg1*) to support in post-inflammatory wound healing response (Martinez and Gordon, 2014). In addition to signaling cascades, metabolic signatures are also cardinal elements of macrophage polarization states (Artyomov et al., 2016; Geeraerts et al., 2017) and emerge as an integral part of their polarization states, affecting and actively communicating with the signaling cascades. Classically polarized macrophages rely on glycolysis, activate the pentose phosphate pathway (PPP), support pyruvate influx into the first span of the tricarboxylic acid (TCA, Krebs) cycle via pyruvate dehydrogenase (PDH), and produce reactive oxygen species (ROS) (Martinez and Gordon, 2014; Meiser et al., 2016). A fragmented TCA cycle supports the decarboxylation of *cis*-aconitate to itaconate (Michelucci et al., 2013; Strelko et al., 2011) and activation of mitochondrial citrate carrier shunt to sustain cytosolic lipid biosynthesis (Feingold et al., 2012; Infantino et al., 2013). Anaplerotic entry of glutamine into the TCA cycle, as well as inhibition of succinate dehydrogenase by itaconate, increases the succinate pool in LPS-polarized cells, which together with ROS stabilizes the transcription factor HIF-1 α to promote pro-inflammatory and glycolytic gene expression (Cordes et al., 2016; Lampropoulou et al., 2016; Mills et al., 2016; Tannahill et al., 2013). In contrast, IL-4-polarized macrophages rely on oxidative phosphorylation sustained by fatty acid β -oxidation or glutamine metabolism (Jha et al., 2015), suppress glycolysis and the PPP, and direct arginine to produce L-ornithine, L-proline, and polyamines, the building blocks of collagen (Geeraerts et al., 2017). More recent work highlights the controversies in substrate utilization of differentially polarized macrophages and indicates the need to reassess the traditional view. For example, β -oxidation of fatty acids in IL-4-polarized macrophages

¹Division of Molecular Medicine, Department of Medicine, University of Minnesota, 401 East River Parkway, MMC 194, Minneapolis, MN 55455, USA

²Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, FL 32827, USA

³Department of Chemistry, Washington University, St. Louis, MO 63110, USA

⁴Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁵Pathobiology Graduate Program, Brown University, Providence, RI 02912, USA

⁶Barshop Institute for Longevity and Aging Studies, Department of Medicine, Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

⁷Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA

⁸These authors contributed equally

⁹Lead Contact

*Correspondence: crawforp@umn.edu

<https://doi.org/10.1016/j.isci.2018.10.029>



may be dispensable for the M2 phenotype (Divakaruni et al., 2018; Gonzalez-Hurtado et al., 2017; Nomura et al., 2016; Van den Bossche and van der Windt, 2018), whereas glucose metabolism may be essential only when fatty acid oxidation is impaired (Huang et al., 2016; Wang et al., 2018). Other metabolites such as α -ketoglutarate can also influence metabolic/epigenetic responses in both LPS- and IL-4-polarized phenotypes (Liu et al., 2017), and although uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), an intermediate in the hexosamine biosynthetic pathway (HBP), has been reported to reflect the M2 state (Jha et al., 2015), it is also enriched in LPS-polarized macrophages (Fei et al., 2016).

The power of liquid chromatography (LC)-high-resolution mass spectrometry (MS)-based untargeted metabolomics to identify and quantify small molecules tightly connected with cell phenotypes has been recently reviewed (Cho et al., 2014; Guijas et al., 2018). The functionality of untargeted metabolomics can be further extended by the addition of stable isotope-labeled substrates, whose labeled atoms can be tracked as metabolic substrates are metabolized in various pathways into downstream products. Most studies rely on alterations in static metabolite pools revealed by (un)targeted metabolomics approaches, or analyze metabolic targets of stable isotopically labeled substrates in a supervised fashion, confirming known pathway activity or quantifying metabolic fluxes (Jang et al., 2018; Zamboni et al., 2015). A more recent approach is to track variations in both total pool sizes and isotopically labeled isotopologues (identical compounds containing different numbers of stable isotope labels incorporated) globally and in a fully unbiased fashion, giving an opportunity to uncover shifts in pathway utilization and with higher resolution than either static or targeted approaches (Weindl et al., 2015). The power of high-mass-accuracy untargeted metabolomics to track stable isotopes supports such screens for unanticipated substrate utilization and reveals differential penetration of label, supporting both discovery and hypothesis-generating observations.

Here, we apply the X¹³CMS bioinformatics (Huang et al., 2014) platform to characterize the shifts in substrate utilization during macrophage polarization by LPS or IL-4. Our data reveal differences in intracellular compartmentalization of substrate utilization that vary with polarization state. The HBP and itaconate biosynthesis are representative pathways, disclosing unrecognized specificities in M1 versus M2 macrophages. Detailed surveillance of distinct ¹³C-labeled substrates revealed that multiple substrates co-opt the same pathways, but utilization is influenced by macrophage polarization state. Finally, our data reveal that the itaconate product of LPS-polarized macrophages is able to reprogram the metabolism of non-inflammatory macrophages. These observations underscore the utility of measuring metabolic states in a high-resolution and unbiased manner and refine our insights into the metabolic behavior of polarized macrophages.

RESULTS

Classically and Alternatively Polarized Macrophages Both Exploit the Hexosamine Biosynthetic Pathway through Unique Metabolic Nodes in Distinct Cellular Compartments

To study the metabolic fates of glucose in macrophages, we cultured primary bone-marrow-derived macrophages (BMDMs) harvested from C57BL/6 mice and first confirmed their phenotypic responses to stimulants of the classical (LPS) and alternative (IL-4) polarization phenotypes (Puchalska et al., 2018). We then used high-mass-accuracy LC/MS untargeted metabolomics to analyze extracts from polarized cells exposed to 10 mM [U-¹³C₆]glucose and analyzed the data using X¹³CMS (Huang et al., 2014). This fully unsupervised approach reveals differences in stable isotopically labeled substrate fate across the metabolome. Out of 8,715 features (ordered pairs of *m/z* and chromatographic retention time that correspond to putative metabolites), X¹³CMS identified 270, 374, and 321 ¹³C-labeled isotopologue groups in control, LPS-, and IL-4-polarized BMDMs, respectively (Table S1). The molecular identity of a subset of these features was assigned by matching MS/MS of standard compounds eluted at same retention time using the same chromatography method (Figure S1A; also see Transparent Methods). Accentuated ¹³C-labeling of glycolytic and PPP intermediates (PPP, also known as the hexose monophosphate shunt) in LPS-polarized macrophages validated this isotope tracing untargeted metabolomics (ITUM) method (Figure S1B) (Geeraerts et al., 2017).

We next performed an unsupervised analysis of the numbers of carbons incorporated from [¹³C]glucose into the metabolome covered by our detection pipeline. Interestingly, when normalized to natural abundance carbon signals (1.1% of all carbon in the environment is ¹³C, depicted as a blue line), all macrophage states exhibited substantially increased numbers of M+3, M+5, M+6, and M+12 isotopologues, indicating




Figure 1. Classically and Alternatively Polarized Macrophages Both Exploit the Hexosamine Biosynthetic Pathway but Differentially Integrate Cytosolic and Mitochondrial Metabolism

(A–D) (A) 10 mM $[U-^{13}\text{C}_6]$ glucose labeling of primary glycolytic intermediates (M+3), intact glucose (M+6, M+12), or glucose-derived sugars (M+5) in unpolarized (control), LPS-polarized (25 ng/mL), or IL-4-polarized (25 ng/mL) wild-type (WT) bone-marrow-derived macrophages (BMDMs) after 24 hr of exposure. 10 mM $[U-^{13}\text{C}_6]$ glucose labeling of (B) UDP-Glc, (C) UMP, and (D) UDP-GlcNac in LPS- or IL-4-polarized WT BMDMs after 24 hr of stimulation ($n = 4/\text{group}$).

Figure 1. Continued

(E) Labeling map with molecular structures of UDP-Glc, UMP, and UDP-GlcNAc depicting integration of the pentose phosphate pathway (PPP, orange dots), mitochondrial metabolism (gray dots), and pyrimidine pathway into hexosamine biosynthetic pathway (HBP, purple dots).

P, phosphate; Glc, glucose; CIC/ACLY, citrate carrier/ATP citrate lyase; PDH, pyruvate dehydrogenase; CS, citrate synthase. Data expressed as the mean \pm standard error of the mean (SEM). Significant differences determined by multiple Student's *t* test with Holm-Sidak correction when compared with control. **p* < 0.05; ***p* < 0.01; ****p* < 0.001; *****p* < 0.0001; ******p* < 0.00001, as indicated.

transit through three-carbon glycolytic intermediates, intact glucose, or glucose-derived five-carbon sugars (possibly from the PPP; Figure 1A). Therefore, we filtered the list of shared features between LPS- and IL-4-polarized macrophages with significant differences in [¹³C]glucose incorporation (any isotopologue difference >0.1 with *p* value < 0.05) (Table S2). Putative identifications of 89 shared and differentially labeled features were assigned using a combination of (1) the PIUMet tool for network integration of untargeted metabolomics data (Pirhaji et al., 2016), (2) molecular formulas and structures capable of generating the observed number of carbon labels in a biological context, and (3) predicted retention time based on chemical similarity to standard compounds (Figure S1A, Tables S1 and S2). From 89 differentially labeled features, 29 putative metabolites were identified. Although the largest number of M+3 isotopologues accumulated in LPS-polarized macrophages (Figure 1A), putative lysophosphatidylethanolamine (LysoPE, 20:5 and 22:5) species exhibited ~50% increased abundance of the M+3 isotopologue in IL-4-polarized macrophages (Figures S2, S3A, and S3B), corresponding to the diversion of [¹³C]glucose-derived glycerone phosphate intermediate into glycerophospholipid metabolism (Figure S2). Five of the 29 metabolites putatively identified and labeled by [¹³C]glucose contained pyrimidine backbone, corresponding to either UDP or CDP moieties in their structures (Figures 1B–1D, S3C, and S3D). The M+6 isotopologue of these compounds represents incorporation of intact [U-¹³C₆]glucose and was especially rich in UDP-Glc (Figures 1B and 1E) or UDP-GlcNAc (Figures 1D and 1E) compounds in IL-4-polarized macrophages. The M+5 isotopologue was upregulated in LPS-polarized macrophages and represents integration of ribose from PPP (in UMP [Figures 1C and 1E], UDP [Figures 1E and S3C], or CDP-ethanolamine [Figures 1E and S3D]). For more complex molecules like UDP-Glc or UDP-GlcNAc, the M+11 isotopologue reflects incorporation of intact [U-¹³C₆]glucose with [¹³C]glucose-derived ribose (from PPP), and the M+8 and M+13 isotopologues add two carbons from a glycolytic-pyruvate-derived acetyl group (Figures 1D and 1E). Robust labeling of intermediates in the pyrimidine metabolic pathway (UDP-Glc, UMP, and UDP) and labeling of UDP-GlcNAc reveals convergence of the cytosolic PPP and HBP in macrophages (Figure 1E). Intriguingly, incorporation of a [¹³C]glucose-derived acetyl group (through pyruvate decarboxylation, condensation to form citrate in the mitochondria, and subsequent tricarboxylate efflux from mitochondria) into UDP-GlcNAc strongly suggests an integration of mitochondrial metabolism to the otherwise cytoplasmic HBP. Thus the HBP is engaged in both LPS- and IL-4-polarized macrophages, but integration and connectivity among cellular compartments is specific to the polarization state, providing insights and extending previous reports of HBP enlistment in either LPS- or IL-4-polarized macrophages (Fei et al., 2016; Jha et al., 2015).

Isotopologue Analysis Reveals Efflux of TCA Cycle Intermediates into Itaconate, GABA, and 2-Hydroxyglutarate in IL-4-Polarized Macrophages

Among the ~500 features labeled, [¹³C]glucose robustly labeled TCA cycle intermediates (Puchalska et al., 2018). A reference isotopologue enrichment scheme (Figure 2A) depicts labeling of TCA cycle and TCA-cycle-derived intermediates by [U-¹³C₆]glucose, through the first TCA cycle turn, via citrate synthase, pyruvate carboxylase, or both together. The total labeled pool of citrate was similar in all macrophage stimulation states, whereas the labeled pools of glutamate and malate were diminished up to 30% in LPS-polarized macrophages compared with control and IL-4-polarized cells (Figure S4A). The M+2 isotopologue of citrate was increased by ~60% in LPS-polarized macrophages, suggesting incorporation of glucose-derived two-carbon acetyl groups into the TCA cycle at first turn and its subsequent efflux (Figures 2A and S4B). Indeed, LPS-polarized macrophages utilize citrate for itaconate biosynthesis and also export citrate via the ATP citrate lyase (ACLY)-catalyzed shuttle to produce lipids in the cytosol (Feingold et al., 2012; Infantino et al., 2013; Strelko et al., 2011). Itaconate is an inhibitor of the microbial glyoxylate shunt enzyme isocitrate lyase, and in mammalian immune cells it is derived from the TCA cycle through the decarboxylation of *cis*-aconitic acid by aconitate decarboxylase (CAD), the product of the immune-responsive 1 (*Irg1*) gene (Cordes et al., 2015; O'Neill, 2015). The decarboxylation of aconitate by CAD yields the M+1 itaconate isotopologue in LPS-polarized macrophages (Figures 2A and 2B). Contribution of label from [¹³C]




Figure 2. Macrophage Efflux of TCA Cycle Intermediates into Itaconate, GABA, and 2-Hydroxyglutarate
 (A–D) (A) A reference isotopologue enrichment scheme depicting labeling of TCA cycle and TCA-cycle-derived intermediates by $[\text{U-}^{13}\text{C}_6]$ glucose (Glc), through the first TCA cycle turn, via citrate synthase (CS, possibility a [black dots]), pyruvate carboxylase (PC, possibility b [orange dots]), or both together (possibility c). Subsequent rows in this scheme illustrate isotopologues obtained from second and third TCA cycle turns only from the citrate synthase incorporation (i.e., derived from CS, possibility a). Gray dots represent ^{12}C . Light orange and green arrow paths depict efflux of the TCA cycle primarily in LPS- and IL-4-polarized macrophages, respectively. 10 mM $[\text{U-}^{13}\text{C}_6]$ glucose labeling of (B) itaconate, (C) gamma-aminobutyric acid (GABA), and (D) 2-hydroxyglutaric acid in unpolarized (control), LPS-polarized (25 ng/mL), or IL-4-polarized (25 ng/mL) WT BMDMs after 24 hr of exposure ($n > 5/\text{group}$). Data expressed as the mean \pm standard error of the mean (SEM). PDH, pyruvate dehydrogenase; CAD, cis-aconitate decarboxylase. Significant differences determined by multiple Student's *t* test with Holm-Sidak correction when compared with control. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.00001$, as indicated.

glucose to the M+4 isotopologue of itaconate arises from anaplerotic entry of $[\text{U-}^{13}\text{C}_6]$ pyruvate into the TCA cycle or through a second turn of the TCA cycle, which was suppressed selectively in LPS-polarized macrophages (Figures 2A and 2B). We also observed increased abundance of the M+3 and M+4 isotopologues of glutamate (a reporter of the TCA cycle intermediate α -ketoglutarate) and malate in IL-4-polarized macrophages versus control and LPS-polarized macrophages, suggesting the retention of $[\text{U-}^{13}\text{C}_6]$ acetyl-CoA in the TCA cycle to support the canonical oxidative metabolism in IL-4-polarized macrophages (Figures 2A, S4C, and S4D). Furthermore, as observed for glutamate and malate, M+4 isotopologues of features




Figure 3. UDP-GlcNAc and Itaconate Biosynthesis Are Increased Primarily in Inflammatory Macrophages

(A) Ion counts of intracellular UDP-GlcNAc from extracts of 1.5×10^6 unpolarized macrophages treated with indicated concentrations of GlcNAc (0–20 mM) ($n = 4$ /group).

(B) Immunoblot for O-GlcNAcylation (normalized to actin) in unpolarized (control), LPS-polarized (25 ng/mL) or IL-4-polarized (25 ng/mL) WT BMDMs after 6, 24, and 48 hr of exposure. WB, western blot.

(C and E) Transcript abundances of (C) *Gfpt1* and (E) *Irg1* genes, which encode the enzymes that catalyze the fate-committing HBP and itaconate biosynthesis reactions in unpolarized or LPS- or IL-4-polarized WT BMDMs after 24 hr of exposure ($n = 4$ /group for *Gfpt1*; $n = 3$ /group for *Irg1*). *Gfpt1* encodes the glutamine:fructose-6-phosphate-aminotransferase enzyme, whereas *Irg1* encodes cis-aconitate decarboxylase.

(D and F) Total pools of (D) UDP-GlcNAc (including UDP-GalNAc) and (F) itaconate normalized to the total amount of proteins (mg) in unpolarized or LPS- or IL-4-polarized WT BMDMs after 24 hr of exposure ($n = 4$ /group).

Data expressed as the mean \pm standard error of the mean (SEM). Significant differences determined by one-way ANOVA. ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, as indicated.

corresponding to gamma-aminobutyric acid (GABA) and 2-hydroxyglutaric acid (2-HG) were selectively increased in IL-4-polarized macrophages, suggesting alternate sites of efflux for TCA cycle intermediates in IL-4-polarized macrophages that are downstream of those in LPS-polarized macrophages (Figures 2A, 2C, and 2D). The efflux of these metabolites in unpolarized and LPS-polarized macrophages is much less pronounced, as indicated by the increased unlabeled fraction of total metabolite pools, when compared with IL-4-polarized macrophages.

UDP-GlcNAc and itaconate are key metabolites of interest in macrophage biology. Tandem MS (MS/MS) confirmed their putative assignments (Figures S4E and S4F), with the caveat that the methods we used do not distinguish between UDP-galactose and UDP-glucose (Figure S4G; also see Transparent Methods). However, the addition of extracellular GlcNAc to the culture medium significantly increased the molar abundance linked to the m/z of the UDP-GlcNAc signal, indicating that a significant portion of this pool corresponds to UDP-GlcNAc (Figures S2 and 3A). Further support that these signals correspond to UDP-GlcNAc come from corresponding isotopologue labeling of a known product downstream of UDP-GlcNAc, N-acetylneuraminic acid (a sialic acid) (Puchalska et al., 2018). The consequences of increased flux through HBP on macrophage function may be manifested in part through downstream O-GlcNAcylation of target proteins. LPS-polarized macrophages exhibit a 4-fold increase in total protein O-GlcNAcylation on western blot (Figure 3B); a 3-fold induction of *Gfpt1* mRNA, which encodes the glutamine:fructose-6-phosphate-aminotransferase enzyme (GFAT) that catalyzes the fate-committing HBP reaction (Figures S2 and 3C); and a $\sim 60\%$ increase in the molar abundance of the total UDP-GlcNAc pool 24 hr after stimulation (Figure 3D). Intriguingly, whereas the molar abundance of the total UDP-GlcNAc pool in IL-4-polarized macrophages was comparable to that in LPS-polarized macrophages, unlike in LPS-polarized macrophages,

Gfpt1 and total protein O-GlcNAcylation were not increased over baseline in IL-4-polarized macrophages (Figures 3B–3D). These results strongly suggest that the HBP is leveraged for distinct purposes in LPS-polarized versus IL-4-polarized macrophages, and indeed IL-4-polarized macrophages may allocate HBP products toward glycosaminoglycan (GAG) metabolism (Puchalska et al., 2018). Thus both destinations of metabolic pathway output and the signature biochemical routes taken to support metabolite production are tightly coupled. The latter requires fully unsupervised and high-resolution isotopologue analysis to reveal, heretofore not performed in polarized macrophages.

Although the total labeled pool of citrate was similar in all macrophage stimulation states (Figure S4A), analysis of itaconate, glutamate, and malate isotopologues (Figures 2B, S4C, and S4D) in macrophages revealed diversion of the citrate pool to itaconate, selectively in the LPS-polarized state. Accordingly, and in agreement with previous reports, *Irg1* mRNA abundance and molar abundance of the total itaconate pool increased ~200- and ~500-fold, respectively, in LPS-polarized macrophages compared with control or IL-4-polarized cells (Figures 3E and 3F). The detection of itaconate synthesis in unpolarized and IL-4-polarized macrophages underscores the sensitivity of an ITUM approach and confirms metabolic plasticity in differentially polarized macrophages.

Multiple Carbon Sources Support the Hexosamine Biosynthetic Pathway and Itaconate Biosynthesis

Much of the work to date on macrophage metabolism has focused on common substrates such as glucose and fatty acids. Ketone bodies represent a significant alternative energy source for cells in both glucose-deficient and glucose-replete states (Puchalska and Crawford, 2017). To determine whether itaconate synthesis and the HBP participate in the metabolic network accessed by ketone bodies, and whether this participation was polarization state specific, we treated control and polarized BMDMs with 1 mM [$^{13}\text{C}_4$]acetoacetate (AcAc) in the presence of 10 mM unlabeled glucose. AcAc is a ketone body that is terminally oxidized in the TCA cycle after activation by the mitochondrial enzyme succinyl-CoA:oxoacid transferase (SCOT, encoded by gene *Oxct1*), which is absolutely required for the mitochondrial conversion of AcAc to acetyl-CoA. SCOT is expressed in all non-hepatocytes, including macrophages (Puchalska and Crawford, 2017). [^{13}C]AcAc robustly labeled intracellular itaconate (M+1 isotopologue) in LPS-polarized macrophages (Figures 4A and 4B) similarly to [^{13}C]glucose (Figure 2B). Labeling of UDP-GlcNAc from [^{13}C]AcAc can be deduced from the molecular structure of UDP-GlcNAc and its biosynthetic pathway (Figure 1E, gray dots; Figure S2). For incorporation into the HBP, mitochondrial [^{13}C]acetyl-CoA is exported to the cytosol as [^{13}C]citrate, where it is converted back to [^{13}C]acetyl-CoA by ACLY, and subsequently condensed with glucosamine-6-phosphate (generated via the catalytic action of GFAT) to ultimately produce the M+2 UDP-GlcNAc isotopologue (Figures 1E, S2, and 4C). In all three conditions, [^{13}C]AcAc predominantly labeled the M+2 isotopologue of UDP-GlcNAc after 6 hr, and more robustly after 24 hr (Figures 4C and 4D). [^{13}C]-labeling of mitochondrial itaconate biosynthesis by [^{13}C]AcAc was completely abolished in both LPS- and IL-4-polarized SCOT knockout (KO) BMDMs (Figure 4E), underscoring the obligate role of mitochondrial metabolism in itaconate synthesis (SCOT KO macrophages exhibited normal signatures of LPS and IL-4 polarizations and metabolize glucose normally (Puchalska et al., 2018)). However, SCOT KO macrophages treated with [^{13}C]AcAc still supported the M+2 isotopologue of UDP-GlcNAc (Figure 4F), suggesting the contribution of cytosolic AcAc-derived acetyl-CoA to UDP-GlcNAc synthesis. Indeed, AcAc can also directly generate a cytosolic pool of acetyl-CoA through an ATP-dependent reaction catalyzed by acetoacetyl-CoA synthetase (AACS), an enzyme whose gene is significantly more induced in SCOT KO BMDMs than in wild-type (WT) BMDMs (Figures 5A and S5A) (Puchalska et al., 2018). Intriguingly, *Gfpt1* and *Irg1* gene expression and molar abundances of both UDP-GlcNAc and itaconate pools were not affected by loss of SCOT or by the presence of AcAc, which indicates functional redundancy of the metabolic network in polarized macrophages (Figures S5B–S5E). Nonetheless, the loss of mitochondrial AcAc oxidation has phenotypic consequences, likely through alteration of GAG metabolism, in a model of tissue macrophage activity in response to high-fat diet stress (Puchalska et al., 2018).

Coordination of Metabolic Pathways across Cellular Compartments Varies by Both Substrate and Macrophage Polarization State

Because tissue macrophages are simultaneously exposed to multiple carbon sources, we assessed which substrates are preferentially directed toward the HBP and itaconate synthesis. The contribution of 10 mM [$^{13}\text{C}_6$]glucose to these pathways was quantified in the presence or absence of unlabeled 1 mM AcAc or unlabeled 0.5 mM octanoate, a fatty acid that enters mitochondria for oxidation independently of




Figure 4. The Ketone Body AcAc Labels the Hexosamine Biosynthetic Pathway and Itaconate Biosynthesis

(A–F) Labeling of itaconate (A, B, and E) and UDP-GlcNAc (C, D, and F) with 1 mM $[\text{U-}^{13}\text{C}_4]$ acetoacetate (AcAc) in unpolarized (control), LPS-polarized (25 ng/mL), or IL-4-polarized (25 ng/mL) WT (A–D) and SCOT KO (E and F) BMDMs after 6 hr (A, C, E, and F) or 24 hr (B and D) of exposure ($n > 6$ /group for itaconate; $n > 4$ /group for UDP-GlcNAc; $n > 3$ /group for SCOT KO). Data expressed as the mean \pm standard error of the mean (SEM). Significant differences determined by multiple Student's *t* test with Holm-Sidak correction when compared with control. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, ***** $p < 0.00001$, as indicated.

carnitine palmitoyltransferase (McGarry and Foster, 1980). Because mitochondrial acetyl-CoA decreases glucose-derived pyruvate entry into the TCA cycle by inhibiting PDH (Cooper et al., 1975), we expected to observe less incorporation of ^{13}C glucose-derived acetyl-CoA if AcAc or octanoate compete for the mitochondrial acetyl-CoA pool (Figure 5A). Indeed, total ^{13}C glucose labeling of TCA intermediates, UDP-GlcNAc, and itaconate in both LPS- and IL-4-polarized macrophages was significantly diminished by unlabeled AcAc or octanoate (Figure 5B–E and Table S3). Decreased ^{13}C glucose-derived labeling of selected metabolites by unlabeled AcAc was similar in both polarization states, with the exception of the M+1 isotopologue of itaconate in IL-4-polarized macrophages (Figure 5B, 5C). However, competition by unlabeled AcAc of the higher-order M+4 isotopologue of itaconate (generated through a combination of anaplerosis from ^{13}C -glucose-derived pyruvate and further turns of the TCA cycle) was evident in IL-4-polarized macrophages (Figure 5C). In IL-4, but in not LPS-polarized macrophages, unlabeled octanoate decreased ^{13}C -labeling of TCA cycle intermediates to a greater extent than unlabeled AcAc (on average $\sim 30\%$ greater reduction of incorporation of the ^{13}C -label) (Figures 5D and 5E), which is consistent with the prime utilization of fatty acids by IL-4-polarized macrophages. Taken together, these observations suggest differential pathway engagement and exchange of metabolites between mitochondrial and cytosolic compartments in macrophages exposed to different substrates and polarization stimuli. These results also reveal effective competition and more avid oxidation of AcAc or octanoate over glucose and highlight the differences in various fuel selection.

SCOT KO macrophages revealed that mitochondrial conversion of AcAc to acetyl-CoA was necessary to contribute to itaconate synthesis, but not the HBP (Figures 4A, 4C, 4E, and 4F). To quantify the extent to which SCOT influences AcAc-derived acetyl-CoA competition with ^{13}C -labeling from ^{13}C glucose, we examined the isotopologue distribution of UDP-GlcNAc and itaconate in the presence or absence of unlabeled 1 mM AcAc in SCOT WT or SCOT KO BMDMs polarized with LPS or IL-4. Deviation in the symmetry of the labeling represents the influence of mitochondrial SCOT metabolism on ^{13}C glucose labeling of these metabolites (Figures 5F, 5G, S5F, and S5G; and Table S3). In both polarization states,










Figure 5. Coordination of Metabolic Pathways across Cellular Compartments Depends on Substrate and Macrophage Polarization State

(A–G) (A) Labeling map depicting integration of mitochondrial ketone body AcAc metabolism with UDP-GlcNAc and itaconate biosynthesis. Competition between 10 mM [$^{13}\text{C}_6$]glucose-derived labeling with unlabeled 1 mM AcAc or 0.5 mM octanoate (Oct) among (B and C) individual UDP-GlcNAc or itaconate isotopologues ($n > 6$ /group) or (D and E) total labeled pools of representative TCA cycle intermediates (a subset of data shown in E also were utilized in Puchalska et al. (2018)) ($n > 6$ /group) in (B and D) LPS-polarized (25 ng/mL) or (C and E) IL-4-polarized (25 ng/mL) wild-type (WT) bone-marrow-derived macrophages (BMDMs) after 24 hr of exposure. Competition between 10 mM [$^{13}\text{C}_6$]glucose-derived labeling and 1 mM unlabeled AcAc of (F) itaconate or (G) UDP-GlcNAc in (F) LPS- or (G) IL-4-polarized WT or SCOT KO BMDMs after 24 hr of exposure ($n = 4$ /group; a portion of the BMDM WT data utilized from Figures 5B and 5C). ACLY, ATP citrate lyase; PDH, pyruvate dehydrogenase; ACO, aconitate hydratase; CAD, cis-aconitate decarboxylase; AACS, acetoacetyl-CoA synthetase; SCOT, succinyl-CoA:oxoacid A transferase. Data expressed as the mean \pm standard error of the mean (SEM). Significant differences determined by multiple Student's t test with Holm-Sidak correction when compared with control. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, ***** $p < 0.00001$, as indicated.

[^{13}C]glucose-derived labeling of itaconate was identical between WT and SCOT KO BMDMs, but competition between [^{13}C]glucose and unlabeled AcAc for contribution to itaconate was completely abolished in SCOT KO macrophages (Figures 5F and S5F). In IL-4-polarized macrophages, even in the absence of unlabeled AcAc, [^{13}C]glucose of UDP-GlcNAc exhibited subtle but statistically significant differences between WT and SCOT KO BMDMs (M+6 and M+8, $p \leq 0.001$), suggesting that the loss of SCOT may affect glucose utilization in the HBP (Figure 5G). The contribution of unlabeled AcAc to UDP-GlcNAc was statistically significant, but only partially diminished in the absence of SCOT, yielding significant changes in the M+8 and M+13 isotopologues (Figures 5G and S5G). Intriguingly, total molar pool sizes of both UDP-GlcNAc and itaconate remained normal in SCOT KO BMDMs (Figures S5D and S5E). This observation suggests pathway-specific compensation from competing substrates and metabolic pathways, e.g., through AACS-mediated cytoplasmic activation of AcAc, supporting acetyl-CoA formation for UDP-GlcNAc, but not for itaconate. On the other hand, glucose-derived acetyl-CoA, all of which is generated in mitochondria via pyruvate decarboxylation, contributes to both UDP-GlcNAc and itaconate.

Itaconate Is Transported into IL-4-Polarized Macrophages Where It Alters Glucose Metabolism

Although our data confirmed that itaconate is primarily an LPS-polarized metabolite, it also suggests small but significant efflux from the TCA cycle toward itaconate biosynthesis in unpolarized and IL-4-polarized macrophages. Itaconate is secreted by LPS-polarized macrophages to inhibit microbial isocitrate lyase, and its potential effects on neighboring brown adipose cells has been recently suggested (Shen et al., 2017; Strelko et al., 2011). Since macrophages exert certain level of plasticity, where LPS-polarized macrophages can mature into IL-4-polarized macrophages upon changes in the microenvironment conditions (Italiani et al., 2014), we tested the impact of [^{13}C]glucose utilization in unpolarized, LPS-polarized, and IL-4-polarized macrophages cultured in the presence of 0.25 mM itaconate in the culture medium. Itaconate is imported into brown adipocytes (Shen et al., 2017), whereas direct transport of itaconate into macrophages has been controversial. Intracellular extracts derived from extensively washed unpolarized and IL-4-polarized macrophages cultured for 24 hr in the presence of 0.25 mM itaconate each exhibited >30-fold increases in the total ion counts corresponding to itaconate (Figure 6A), indicating robust uptake of the metabolite. In contrast, the total ion count of itaconate in intracellular extracts of LPS-polarized macrophages cultured in the presence of 0.25 mM itaconate increased only by 10%. To determine whether this much smaller increase was a result of decreased import or diminished endogenous itaconate synthesis, we leveraged the isotopologue labeling pattern of endogenously produced itaconate, generated from [^{13}C]glucose, in the presence of unlabeled 0.25 mM exogenous itaconate. Indeed, intracellular extracts from unpolarized and IL-4-polarized macrophages both exhibited nearly 3-fold dilution of the predominantly M+1 itaconate isotopologue produced from [^{13}C]glucose (Figures 6B and S6A), suggesting extensive competition from exogenous itaconate in these conditions. However, intracellular extracts from LPS-polarized macrophages exhibited only 20% dilution of the M+1 itaconate isotopologue, suggesting limited import of exogenous itaconate and limited inhibition of endogenous itaconate synthesis in LPS-polarized macrophages by exogenous itaconate (Figure 6C). Taken together, extracellular itaconate is imported into macrophages down a concentration gradient.

To determine if extracellular itaconate influences the metabolic profile of the importing cells, we analyzed the fates of 10 mM [^{13}C]glucose in the presence or absence of 0.25 mM extracellular itaconate (Figure 6D). Putative




Figure 6. Itaconate Is Transported into Alternatively Polarized Macrophages Where It Alters Glucose Metabolism

(A–C) (A) Total ion counts of intracellular itaconate (ITA) in unpolarized (control), LPS-polarized (25 ng/mL), or IL-4-polarized (25 ng/mL) WT BMDMs after 24 hr of exposure with or without the addition of 0.25 mM of exogenous itaconate (n = 4/group). 10 mM [¹³C₆]glucose-derived labeling of itaconate in the presence or absence of unlabeled 0.25 mM itaconate in (B) IL-4- and (C) LPS-polarized WT BMDMs after 24 hr of exposure (n = 4/group). (D) Venn diagram depicting changes in the numbers of features labeled by 10 mM [¹³C₆]glucose in the presence (versus absence) of 0.25 mM exogenous unlabeled itaconate in unpolarized and LPS- and IL-4-polarized WT BMDMs after 24 hr of exposure (n = 4/group).

Figure 6. Continued

(E–G) (E) 10 mM [U-¹³C₆]glucose-derived labeling of citrate in LPS- and IL-4-polarized WT BMDMs in the presence or absence of 0.25 mM exogenous unlabeled itaconate after 24 hr of exposure (n = 4/group). Total ion counts of (F) citrate and (G) succinate in unpolarized or LPS- or IL-4-polarized WT BMDMs after 24 hr of exposure with or without the addition of 0.25 mM exogenous itaconate (n = 4/group).

Data expressed as the mean ± standard error of the mean (SEM). Significant differences determined by Student's t test or multiple Student's t test with Holm-Sidak correction when compared to control. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, *****p < 0.00001, as indicated.

identifications for 9, 5, or 17 of the 24, 21, or 60 total isotopologue groups competed by unlabeled itaconate in unpolarized, LPS-polarized, and IL-4-polarized macrophages, respectively, were assigned using PIUMet (Table S4). IL-4-polarized macrophages exhibited the largest number (44, compared with 11 or 12 in unpolarized and LPS-polarized macrophages, respectively) of [¹³C]glucose-labeled features whose labeling pattern was changed by the presence of exogenous unlabeled itaconate (Figure 6D). Among the affected metabolites were LysoPE species, detected in unpolarized [(16:0); (20:4); (22:4)] and LPS-polarized macrophages, and arachidonic acid/nicotinamide ribonucleotide, citric acid, and UDP-GlcNAc, detected in IL-4-polarized macrophages (Table S4). Total labeling of UDP-GlcNAc increased slightly (18%) in the presence of extracellular itaconate in IL-4-polarized macrophages (Figure S6B), whereas the M+2 citrate isotopologue was increased 18% and the unlabeled isotopologue decreased 24% (Figure 6E). Because (1) labeling of second-span TCA cycle intermediates, including malate, was not affected (Figure S6C); (2) succinate and citrate pool sizes were not altered (Figures 6F and 6G); and (3) ¹³C-labeling of lactate was not affected (Figure S6D), neither glycolysis nor pyruvate decarboxylation was influenced by extracellular itaconate, although citrate efflux from mitochondria was stimulated. Taken together, these data suggest that extracellular itaconate can be imported into macrophages that do not actively synthesize it, influencing their metabolism. Nonetheless, we did not observe evidence of succinate dehydrogenase inhibition in importing cells, as has been attributed to endogenous itaconate in classically polarized macrophages (Cordes et al., 2016; Lampropoulou et al., 2016).

DISCUSSION

Differentially polarized macrophages reveal distinct metabolic signatures that cohesively integrate their functions (Artyomov et al., 2016; Geeraerts et al., 2017; Kelly and O'Neill, 2015; Martinez and Gordon, 2014). The data presented herein reveal substrate- and polarization-state-dependent mechanisms through which glucose and ketone body metabolisms are interwoven within and between cellular compartments. Applying a multi-substrate ¹³C-ITUM pipeline enabled (1) unbiased determination of the chemical space penetrated by labeled substrates in an unsupervised mode (also see Puchalska et al. (2018)) and (2) based on inferences conferred by ¹³C-labeled isotopologues, further insight into variations in relative contributions of convergent metabolic pathways. These observations provide a foundation for determining how macrophages integrate metabolic pathways such as the PPP, pyrimidine metabolism, HBP, the TCA cycle, and lipid metabolism in different polarization states. The biosynthesis of some metabolites, such as itaconate, occurred uniquely in macrophage mitochondria, whereas other metabolites integrated mitochondrial and cytosolic nodes into biosynthetic pathways in a polarization-state-specific manner. Genetic interruption of one orchestrated metabolic pathway in macrophage metabolism led to adaptations in cross talk between mitochondria and cytosol. Substrates competing for contribution to the same metabolic pathway are allocated differentially, and in a polarization-state-specific manner, and macrophages are remarkably resilient by retaining a core metabolome, even when access to a substrate was interrupted. Finally, our results reveal a potentially paracrine metabolic role for the LPS-polarized macrophage metabolite itaconate on neighboring cells that do not synthesize it.

The most commonly applied metabolomics approaches are label-free targeted and untargeted metabolomics technologies that survey for variations in the "snapshot" abundance of total metabolite pools. Although these approaches are powerful, they do not reveal direct insight into metabolic reaction rates, or how metabolic pathways are connected. Fluctuations in static metabolite abundances may remain normal or minimally changed, despite considerable changes in reaction rates and/or pathway orchestration. However, emerging approaches that integrate constraint-based modeling of metabolic flux, e.g., flux balance analysis, and static metabolomics datasets are emerging and will increase data harvest from metabolomics datasets (Bordbar et al., 2017).

The use of stable isotope labels has traditionally been applied to targeted approaches that allow reaction rate calculations either using steady-state or non-stationary kinetic analyses, quantifying metabolic

flux measured in $\text{mol} \cdot \text{min}^{-1} \cdot \text{unit biomass}^{-1}$ (Jazmin and Young, 2013; Zamboni et al., 2015). Stable isotopically labeled “fluxomics” approaches attempt to quantify broader substrate-product rate relationships across the metabolome (Weindl et al., 2016). Newer pipelines that integrate stable isotope labels with untargeted metabolomics also allow model-free analysis supporting metabolome-wide, discovery-based, and hypothesis-generating observations, where the penetration of the stable isotope (e.g., ^{13}C) into the metabolome is quantified in an unsupervised manner without the calculation of metabolic flux (Zamboni, 2011). Indeed in metabolic pathways, particularly those outside of the central carbon metabolism, differential penetration of ^{13}C -label into the metabolite pool is independent of changes in flux, while unique insight can be gained from metabolome-wide fractional enrichments of specific isotopologues, revealing (1) specificity of relative contributions from converging pathways, (2) *in vivo* functional connectivity of metabolic pathways, and (3) compensatory mechanisms triggered under disruptive conditions (Weindl et al., 2015). Stable isotope-assisted untargeted metabolomics approaches commonly reveal markedly divergent chemical features, compared with label-free approaches (Huang et al., 2014). This is a key distinction, because “untargeted” labeling approaches commonly first generate static untargeted metabolomics datasets to uncover metabolites with varying pool sizes across conditions that then drive a secondary targeted analysis of labeling from an isotopically enriched substrate. This pipeline describes a previous approach taken in alternatively polarized macrophages (Jha et al., 2015). Instead the experiments presented here track label in a fully unsupervised manner, metabolome wide, revealing insight into pathways that do not require altered intermediate pool sizes. Furthermore, unique insights conferred by the ITUM pipeline were evident by comparing competition between substrates such as glucose, AcAc, or octanoate contribution to numerous pathways, including the TCA cycle, the HBP, and itaconate biosynthesis. These shifts would not have been visible through label-free targeted or untargeted approaches.

It is likely that the diversity of substrates presented, and the capacity to metabolize them, influences both canonical signaling and metabolic pathways in both classically and alternatively polarized macrophages. Indeed, substrate selection and metabolism may confer greater influence on anabolic pathways and provide a repertoire of covalent modifiers that coordinate downstream signaling processes (Puchalska and Crawford, 2017; Schoors et al., 2015; Wong et al., 2017). For example, untargeted analysis of features labeled by [^{13}C]glucose revealed possible efflux from the TCA cycle from α -ketoglutarate (M+4 isotopologue) to GABA and 2-HG, especially in alternatively polarized macrophages. GABA is produced by the glutamate decarboxylases (GAD65 or GAD67) from glutamate (Jin et al., 2013). Although GABA primarily serves as a central nervous system neurotransmitter, macrophages also express GAD65 (Bhat et al., 2010). The production of 2-HG from the TCA cycle usually occurs from isocitrate via isocitrate dehydrogenase 1 or 2 (producing D-2-HG) mutants or by lactate dehydrogenase A (producing L-2-HG) or malate dehydrogenase during hypoxia (Intlekofer et al., 2017). Both 2-HG enantiomers inhibit a large family of α -ketoglutarate-dependent enzymes that modulate chromatin, hypoxia-inducible factors, extracellular matrix, and DNA repair (Losman and Kaelin, 2013). Although labeling of these putative metabolites requires follow-up, only a fully unsupervised analysis raises attention to these metabolites.

In our studies, despite equimolar abundances of the UDP-GlcNAc pool in LPS and IL-4-polarized macrophages, *Gfpt1* gene expression, the magnitude of O-glycosylation, and the magnitude of [^{13}C]glucose labeling of downstream intermediates all supported greater HBP biosynthetic activity in LPS-polarized macrophages, suggesting a lower rate of UDP-GlcNAc turnover in IL-4-polarized macrophages (Baudoin and Issad, 2015; Wang et al., 2016). Our findings in this and a companion study (Puchalska et al., 2018) support a significant role of the HBP in both polarization states, to be distinguished from independent studies, suggesting that this pathway was most relevant in either LPS- or IL-4-polarized macrophages (Fei et al., 2016; Jha et al., 2015). It is also important to note that UDP-galactose and UDP-glucose can be interconverted through the Leloir pathway, and the *m/z* signal we detected cannot be distinguished by the methods we employed. UDP-GlcNAc alone is an intermediate in the HBP, supporting N- and O-linked glycosylations, whereas both UDP-GalNAc and UDP-GlcNAc are substrates for O-linked glycosylation, and for the synthesis of GAGs, disaccharide polymers of variably sulfated amino sugars (e.g., GlcNAc or GalNAc) conjugated with either a uronic sugar or galactose. GAG metabolism could be central to alternatively polarized macrophage function, where mitochondrial ketone metabolism is essential, and particularly important in the coordination of the fibrotic response (Puchalska et al., 2018). ITUM revealed that GAG metabolism is altered in IL-4-polarized macrophages incompetent to convert AcAc to acetyl-CoA in mitochondria, and thus future studies are needed to interrogate prospective exchange of

intermediates between the HBP and the Leloir pathway, and how this might influence GAG anabolism in macrophages.

Itaconate is an endogenous signaling molecule with a myriad of targets (Murphy and O'Neill, 2018). Recent observations indicate roles of itaconate metabolism in vitamin B12 inactivation, activation of NRF2 anti-inflammatory transcription factor, and inhibition of succinate dehydrogenase activity by itaconate secretion in LPS-polarized macrophages (Bambouskova et al., 2018; Cordes et al., 2016; Mills et al., 2016, 2018; Shen et al., 2017). Our observations incorporating exogenous 0.25 mM itaconate in the culture medium of primary BMDMs support the possibility that itaconate may be exchanged among cells, and clearly demonstrate import of itaconate into primary macrophages. Shen et al. demonstrated itaconate (1–2 mM) import into adipocytes; Nair et al. demonstrated an effect of exogenous itaconate on macrophage gene expression without testing whether or not it was imported; and Cordes and colleagues tested a minimum of 5 mM itaconate in RAW 264.7 macrophages (Cordes et al., 2016; Nair et al., 2018; Shen et al., 2017). However, the question of macrophage import of exogenous itaconate has persisted, as investigators have employed “membrane-permeable” itaconate derivatives, including 4-octyl itaconate (Mills et al., 2018) or dimethyl-itaconate (Bambouskova et al., 2018; Lampropoulou et al., 2016). The use of itaconate chemical derivatives to mimic itaconate cellular import, metabolism, and signaling raises concern for (1) off-target effects of the derivative that are independent of itaconate or its natural fates and (2) whether the derivatives actually mimic itaconate. Indeed, dimethyl itaconate may not be metabolized to itaconate (ElAzzouny et al., 2017). Although we observed that exogenous 0.25 mM itaconate was imported into BMDMs, we did not observe succinate accumulation in these recipient cells, or biochemical evidence that supported succinate dehydrogenase inhibition, possibly due to the low concentration of exogenous itaconate utilized in our experiments. Nonetheless, our results raise the possibility that itaconate may be exchanged among macrophages, or LPS-polarized macrophages, and any neighboring cell that does not produce significant itaconate quantities, influencing both substrate metabolism and signaling in the recipient cell, a notion supported by altered fates of [¹³C]glucose in IL-4-polarized macrophages cultured in the presence of exogenous itaconate.

The role of substrate selection in macrophage polarization remains of unresolved significance. The preference to oxidize octanoate over glucose in IL-4-polarized macrophages confirms higher engagement of fatty acid oxidation in alternatively polarized macrophages (Vats et al., 2006), although macrophages unable to oxidize long-chain fatty acids exhibit no impairment in the execution of the IL-4 macrophage program, and adapt through use of alternative substrates (Divakaruni et al., 2018; Gonzalez-Hurtado et al., 2017; Nomura et al., 2016; Van den Bossche and van der Windt, 2018). The collective findings presented here, and in Puchalska et al. (2018) reveal the ability of macrophages to enlist the ketone body AcAc in the execution of its metabolic functions. Ketone bodies are commonly considered to be of relevance only in carbohydrate-restricted states, although they play metabolic and signaling roles in carbohydrate-replete conditions (Puchalska and Crawford, 2017). It is likely that the loss of mitochondrial conversion of AcAc to acetyl-CoA via SCOT KO has no impact on bioenergetic homeostasis in the IL-4-polarized macrophages, a polarization state in which SCOT is specifically induced at the transcriptional level (Puchalska et al., 2018). Nonetheless, as in cardiac myocytes lacking SCOT, alternatively polarized macrophages lacking SCOT simply switch to other available substrates to support bioenergetic requirements (Schugar et al., 2014). The impact of losing SCOT is instead observed through impaired procession of AcAc metabolites into downstream pathways, as livers of mice whose macrophages lack SCOT exhibit an accelerated fibrogenic phenotype that is linked to impairments in GAG metabolism.

Limitation of Study

ITUM, using high-resolution mass spectrometry, provides a powerful platform for quantifying (1) differential penetration of label into the metabolome of cells or tissues from varying conditions; (2) substrate competition across the metabolome, and its variance among conditions; and (3) via isotopologue analysis, differential configuration of pathway connectivity. ITUM does not reveal biochemical reaction or biomass synthesis rates, and thus differential fractional enrichment may not reflect variation in metabolic flux. In addition, the consequences of imported itaconate on macrophage metabolism and signaling will need comparison to the effects of endogenously produced itaconate, and to those of exogenous itaconate adducts that are commonly administered in an attempt to increase intracellular itaconate concentrations.

METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Transparent Methods, six figures, and four tables and can be found with this article online at <https://doi.org/10.1016/j.isci.2018.10.029>.

ACKNOWLEDGMENTS

The authors thank Alisa Nelson for helpful discussions, J. Matthew Gandy and Matthew Longo for assistance with mouse husbandry, Laura Kyro for graphics expertise, and Peter Phelan for guidance on primary macrophage isolation and culture. This work was supported in part by grants from the NIH (DK091538, CA235482, ES028365, and OD024624).

AUTHOR CONTRIBUTIONS

Conceptualization, P.P., X. Huang, and P.A.C.; Methodology, P.P., X. Huang, S.M., G.J.P., and P.A.C.; Investigation, P.P., X. Huang, S.M.; Resources, P.A.C.; Writing – Original Draft, P.P. and P.A.C.; Writing – Review & Editing, all authors; Visualization, P.P., X. Huang, and P.A.C.; Supervision, X. Han, G.J.P. and P.A.C.; Funding Acquisition, P.A.C.

DECLARATION OF INTERESTS

The authors declare no conflict of interest.

Received: February 22, 2018

Revised: August 21, 2018

Accepted: October 29, 2018

Published: November 30, 2018

REFERENCES

- Artyomov, M.N., Sergushichev, A., and Schilling, J.D. (2016). Integrating immunometabolism and macrophage diversity. *Semin. Immunol.* *28*, 417–424.
- Bambouskova, M., Gorvel, L., Lampropoulou, V., Sergushichev, A., Loginicheva, E., Johnson, K., Korenfeld, D., Mathyer, M.E., Kim, H., Huang, L.H., et al. (2018). Electrophilic properties of itaconate and derivatives regulate the I κ B β -ATF3 inflammatory axis. *Nature* *556*, 501–504.
- Baudoin, L., and Issad, T. (2015). O-GlcNAcylation and inflammation: a vast territory to explore. *Front. Endocrinol. (Lausanne)* *5*, 235.
- Bhat, R., Axtell, R., Mitra, A., Miranda, M., Lock, C., Tsien, R.W., and Steinman, L. (2010). Inhibitory role for GABA in autoimmune inflammation. *Proc. Natl. Acad. Sci. U S A* *107*, 2580–2585.
- Bordbar, A., Yurkovich, J.T., Paglia, G., Rolfsson, O., Sigurjonsson, O.E., and Palsson, B.O. (2017). Elucidating dynamic metabolic physiology through network integration of quantitative time-course metabolomics. *Sci. Rep.* *7*, 46249.
- Cho, K., Mahieu, N.G., Johnson, S.L., and Patti, G.J. (2014). After the feature presentation: technologies bridging untargeted metabolomics and biology. *Curr. Opin. Biotechnol.* *28*, 143–148.
- Cooper, R.H., Randle, P.J., and Denton, R.M. (1975). Stimulation of phosphorylation and inactivation of pyruvate dehydrogenase by physiological inhibitors of the pyruvate dehydrogenase reaction. *Nature* *257*, 808–809.
- Cordes, T., Michelucci, A., and Hiller, K. (2015). Itaconic acid: the surprising role of an industrial compound as a mammalian antimicrobial metabolite. *Annu. Rev. Nutr.* *35*, 451–473.
- Cordes, T., Wallace, M., Michelucci, A., Divakaruni, A.S., Sapcaru, S.C., Sousa, C., Koseki, H., Cabrales, P., Murphy, A.N., Hiller, K., and Metallo, C.M. (2016). Immunoresponsive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels. *J. Biol. Chem.* *291*, 14274–14284.
- Divakaruni, A.S., Hsieh, W.Y., Minarrieta, L., Duong, T.N., Kim, K.K.O., Desousa, B.R., Andreyev, A.Y., Bowman, C.E., Caradonna, K., Dranka, B.P., et al. (2018). Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis. *Cell Metab.* *28*, 490–503.e7.
- ElAzzouy, M., Tom, C.T.M.B., Evans, C.R., Olson, L.L., Tanga, M.J., Gallagher, K.A., Martin, B.R., and Burant, C.F. (2017). Dimethyl itaconate is not metabolized into itaconate intracellularly. *J. Biol. Chem.* *292*, 4766–4769.
- Fei, F., Lee, K.M., McCarry, B.E., and Bowdish, D.M. (2016). Age-associated metabolic dysregulation in bone marrow-derived macrophages stimulated with lipopolysaccharide. *Sci. Rep.* *6*, 22637.
- Feingold, K.R., Shigenaga, J.K., Kazemi, M.R., McDonald, C.M., Patzek, S.M., Cross, A.S., Moser, A., and Grunfeld, C. (2012). Mechanisms of triglyceride accumulation in activated macrophages. *J. Leukoc. Biol.* *92*, 829–839.
- Geeraerts, X., Bolli, E., Fendt, S.M., and Van Ginderachter, J.A. (2017). Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. *Front. Immunol.* *8*, 289.
- Gonzalez-Hurtado, E., Lee, J., Choi, J., Selen Alpergin, E.S., Collins, S.L., Horton, M.R., and Wolfgang, M.J. (2017). The loss of macrophage fatty acid oxidation does not potentiate systemic metabolic dysfunction. *Am. J. Physiol. Endocrinol. Metab.* *312*, E381–E393.
- Guijas, C., Montenegro-Burke, J.R., Warth, B., Spilker, M.E., and Siuzdak, G. (2018). Metabolomics activity screening for identifying metabolites that modulate phenotype. *Nat. Biotechnol.* *36*, 316–320.
- Huang, S.C., Smith, A.M., Everts, B., Colonna, M., Pearce, E.L., Schilling, J.D., and Pearce, E.J. (2016). Metabolic reprogramming mediated by the mTORC2-irf4 signaling axis is essential for macrophage alternative activation. *Immunity* *45*, 817–830.
- Huang, X., Chen, Y.J., Cho, K., Nikolskiy, I., Crawford, P.A., and Patti, G.J. (2014). X13CMS: global tracking of isotopic labels in untargeted metabolomics. *Anal. Chem.* *86*, 1632–1639.

- Infantino, V., Iacobazzi, V., Palmieri, F., and Menga, A. (2013). ATP-citrate lyase is essential for macrophage inflammatory response. *Biochem. Biophys. Res. Commun.* **440**, 105–111.
- Intlekofer, A.M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A.S., Salah, S., Gunner, M.R., Chodera, J.D., Cross, J.R., and Thompson, C.B. (2017). L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. *Nat. Chem. Biol.* **13**, 494–500.
- Italiani, P., Mazza, E.M., Lucchesi, D., Cifola, I., Gemelli, C., Grande, A., Battaglia, C., Biccato, S., and Boraschi, D. (2014). Transcriptomic profiling of the development of the inflammatory response in human monocytes in vitro. *PLoS One* **9**, e87680.
- Jang, C., Chen, L., and Rabinowitz, J.D. (2018). Metabolomics and isotope tracing. *Cell* **173**, 822–837.
- Jazmin, L.J., and Young, J.D. (2013). Isotopically nonstationary ¹³C metabolic flux analysis. *Methods Mol. Biol.* **985**, 367–390.
- Jha, A., Huang, S., Sergushichev, A., Lampropoulou, V., Ivanova, Y., Loginicheva, E., Chmielewski, K., Stewart, K., Ashall, J., Everts, B., et al. (2015). Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. *Immunity* **42**, 419–430.
- Jin, Z., Mendu, S.K., and Birnir, B. (2013). GABA is an effective immunomodulatory molecule. *Amino Acids* **45**, 87–94.
- Kelly, B., and O'Neill, L.A. (2015). Metabolic reprogramming in macrophages and dendritic cells in innate immunity. *Cell Res.* **25**, 771–784.
- Kim, K., Zhang, N., Choi, K., and Randolph, G. (2016). Homegrown macrophages. *Immunity* **45**, 468–470.
- Lampropoulou, V., Sergushichev, A., Bambouskova, M., Nair, S., Vincent, E., Loginicheva, E., Cervantes-Barragan, L., Ma, X., Huang, S., Griss, T., et al. (2016). Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. *Cell Metab.* **24**, 158–166.
- Liu, P.S., Wang, H., Li, X., Chao, T., Teav, T., Christen, S., Di Conza, G., Cheng, W.C., Chou, C.H., Vavakova, M., et al. (2017). Alpha-Ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. *Nat. Immunol.* **18**, 985–994.
- Losman, J.A., and Kaelin, W.G., Jr. (2013). What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. *Genes Dev.* **27**, 836–852.
- Martinez, F.O., and Gordon, S. (2014). The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep.* **6**, 13.
- McGarry, J.D., and Foster, D.W. (1980). Regulation of hepatic fatty acid oxidation and ketone body production. *Annu. Rev. Biochem.* **49**, 395–420.
- Meiser, J., Krämer, L., Sapcaru, S.C., Battello, N., Ghelfi, J., D'Herouel, A.F., Skupin, A., and Hiller, K. (2016). Pro-inflammatory macrophages sustain pyruvate oxidation through pyruvate dehydrogenase for the synthesis of itaconate and to enable cytokine expression. *J. Biol. Chem.* **291**, 3932–3946.
- Michelucci, A., Cordes, T., Ghelfi, J., Pailot, A., Reiling, N., Goldmann, O., Binz, T., Wegner, A., Tallam, A., Rausell, A., et al. (2013). Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. *Proc. Natl. Acad. Sci. U S A* **110**, 7820–7825.
- Mills, E.L., Kelly, B., Logan, A., Costa, A.S.H., Varma, M., Bryant, C.E., Tourlomousis, P., Dabritz, J.H.M., Gottlieb, E., Latorre, I., et al. (2016). Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. *Cell* **167**, 457–470.e13.
- Mills, E.L., Ryan, D.G., Prag, H.A., Dikovskaya, D., Menon, D., Zaslona, Z., Jedrychowski, M.P., Costa, A.S.H., Higgins, M., Hams, E., et al. (2018). Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. *Nature* **556**, 113–117.
- Murphy, M.P., and O'Neill, L.A.J. (2018). Krebs cycle reimagined: the emerging roles of succinate and itaconate as signal transducers. *Cell* **174**, 780–784.
- Nair, S., Huynh, J.P., Lampropoulou, V., Loginicheva, E., Esaulova, E., Gounder, A.P., Boon, A.C.M., Schwarzkopf, E.A., Bradstreet, T.R., Edelson, B.T., et al. (2018). Irg1 expression in myeloid cells prevents immunopathology during *M. tuberculosis* infection. *J. Exp. Med.* **215**, 1035–1045.
- Nomura, M., Liu, J., Rovira, I.I., Gonzalez-Hurtado, E., Lee, J., Wolfgang, M.J., and Finkel, T. (2016). Fatty acid oxidation in macrophage polarization. *Nat. Immunol.* **17**, 216–217.
- O'Neill, L.A. (2015). A broken krebs cycle in macrophages. *Immunity* **42**, 393–394.
- Pirhaji, L., Milani, P., Leidl, M., Curran, T., Avila-Pacheco, J., Clish, C.B., White, F.M., Saghatelian, A., and Fraenkel, E. (2016). Revealing disease-associated pathways by network integration of untargeted metabolomics. *Nat. Methods* **13**, 770–776.
- Puchalska, P., Martin, S.E., Huang, X., Lengfeld, J., Graham, M., Daniel, B., Nagy, L., Han, X., Patti, G., and Crawford, P.A. (2018). Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis. *Cell Metab.* <https://doi.org/10.1016/j.cmet.2018.10.015>.
- Puchalska, P., and Crawford, P.A. (2017). Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. *Cell Metab.* **25**, 262–284.
- Schoors, S., Bruning, U., Missiaen, R., Queiroz, K.C., Borgers, G., Elia, I., Zecchin, A., Cantelmo, A.R., Christen, S., Goveia, J., et al. (2015). Fatty acid carbon is essential for dNTP synthesis in endothelial cells. *Nature* **520**, 192–197.
- Schugar, R.C., Moll, A.R., André d'Avignon, D., Weinheimer, C.J., Kovacs, A., and Crawford, P.A. (2014). Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. *Mol. Metab.* **3**, 754–769.
- Shen, H., Campanello, G.C., Flicker, D., Grabarek, Z., Hu, J., Luo, C., Banerjee, R., and Mootha, V.K. (2017). The human knockout gene CLYBL connects itaconate to vitamin B12. *Cell* **171**, 771–782.e11.
- Strelko, C.L., Lu, W., Dufort, F.J., Seyfried, T.N., Chiles, T.C., Rabinowitz, J.D., and Roberts, M.F. (2011). Itaconic acid is a mammalian metabolite induced during macrophage activation. *J. Am. Chem. Soc.* **133**, 16386–16389.
- Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., McGettrick, A.F., Goel, G., Frezza, C., Bernard, N.J., Kelly, B., Foley, N.H., et al. (2013). Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature* **496**, 238–242.
- Tur, J., Vico, T., Lloberas, J., Zorzano, A., and Celada, A. (2017). Chapter One - Macrophages and mitochondria: a critical interplay between metabolism, signaling, and the functional activity. *Adv. Immunol.* **133**, 1–36.
- Van den Bossche, J., and van der Windt, G.J.W. (2018). Fatty acid oxidation in macrophages and T cells: time for reassessment? *Cell Metab.* **28**, 538–540.
- Vats, D., Mukundan, L., Odegaard, J.I., Zhang, L., Smith, K.L., Morel, C.R., Greaves, D.R., Murray, P.J., and Chawla, A. (2006). Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. *Cell Metab.* **4**, 13–24.
- Wang, F., Zhang, S., Vuckovic, I., Jeon, R., Lerman, A., Folmes, C.D., Dzeja, P.P., and Herrmann, J. (2018). Glycolytic stimulation is not a requirement for M2 macrophage differentiation. *Cell Metab.* **28**, 463–475.e4.
- Wang, X., Yuan, Z.F., Fan, J., Karch, K.R., Ball, L.E., Denu, J.M., and Garcia, B.A. (2016). A novel quantitative mass spectrometry platform for determining protein O-GlcNAcylation dynamics. *Mol. Cell. Proteomics* **15**, 2462–2475.
- Weindl, D., Cordes, T., Battello, N., Sapcaru, S.C., Dong, X., Wegner, A., and Hiller, K. (2016). Bridging the gap between non-targeted stable isotope labeling and metabolic flux analysis. *Cancer Metab.* **4**, 10.
- Weindl, D., Wegner, A., and Hiller, K. (2015). Metabolome-wide analysis of stable isotope labeling-is it worth the effort? *Front. Physiol.* **6**, 344.
- Wong, B.W., Wang, X., Zecchin, A., Thienpont, B., Cornelissen, I., Kalucka, J., Garcia-Caballero, M., Missiaen, R., Huang, H., Bruning, U., et al. (2017). The role of fatty acid beta-oxidation in lymphangiogenesis. *Nature* **542**, 49–54.
- Zamboni, N., Saghatelian, A., and Patti, G.J. (2015). Defining the metabolome: size, flux, and regulation. *Mol. Cell* **58**, 699–706.
- Zamboni, N. (2011). ¹³C metabolic flux analysis in complex systems. *Curr. Opin. Biotechnol.* **22**, 103–108.

ISCI, Volume 9

Supplemental Information

Isotope Tracing Untargeted Metabolomics Reveals

Macrophage Polarization-State-Specific Metabolic

Coordination across Intracellular Compartments

Patrycja Puchalska, Xiaojing Huang, Shannon E. Martin, Xianlin Han, Gary J. Patti, and Peter A. Crawford

SUPPLEMENTAL INFORMATION

SUPPLEMENTAL FIGURES

Figure S1 (related to Fig. 1). Confirmation of metabolite identities and canonical metabolic responses of macrophages to LPS and IL-4 polarization. (A) List of the metabolites with their corresponding m/z detected in negative mode, retention time (RT) and identification method. Metabolites were identified by comparing m/z , MS/MS, and RT to their standards or similar metabolite listed in the table. (B) Labeling of representative pentose phosphate pathway (PPP), and glycolytic intermediates with 10 mM [U- $^{13}\text{C}_6$]glucose in unpolarized (Control), LPS (25 ng/mL) or IL-4 (25 ng/mL) polarized wild type (WT) bone marrow derived macrophages (BMDMs) after 6 hours of exposure ($n > 2$ /group). Panel utilized also in (Puchalska et al., 2018). HP: Hexose-phosphate; SDP-7-P: Sedoheptulose-7-phosphate; Significant differences determined by Multiple Student's t test with Holm-Sidak correction when compared to M0 (unpolarized control macrophages). Data expressed as the mean \pm standard error of the mean (SEM). * $p < 0.05$; ***, $p < 0.001$, as indicated.

Figure S2 (related to Fig. 1, 3). Map of glucose utilization through key metabolic pathways in macrophages. Schematic representation of glucose utilization pathways in macrophages. P-phosphate; GFAT: glutamine:fructose-6-phosphate-aminotransferase enzyme; OGT: O-linked N-acetylglucosamine (GlcNAc) transferase; OGA: O-GlcNAc-specific β -hexosaminidase; Lyso-phosphatidylethanolamine (Lyso-PE).

Figure S3 (related to Fig. 1). Differential incorporation of [^{13}C]glucose-derived label in polarized macrophages. 10 mM [U- $^{13}\text{C}_6$]glucose derived labeling and molecular structure (red

dots represent [¹³Carbon incorporation]) of **(A-B)** Lyso-phosphatidylethanolamine (Lyso-PE) (20:4 or 22:5) species, **(C)** UDP or **(D)** CDP-Etanolamine in LPS (25 ng/mL) or IL-4 (25 ng/mL) polarized WT BMDMs after 24 hours of exposure (n=4/group). Significant differences determined by Multiple Student's t-test with Holm-Sidak correction when compared to M0 (unpolarized control macrophages) or one-way ANOVA. Data expressed as the mean ± standard error of the mean (SEM). **, $p < 0.01$; *****, $p < 0.00001$, as indicated.

Figure S4 (related to Fig. 2-3). Glucose utilization in TCA cycle and confirmation of UDP-GlcNAc and itaconate identifications. **(A)** Labeling of representative TCA cycle intermediates with 10 mM [U-¹³C₆]glucose in unpolarized (Control), LPS (25 ng/mL) or IL-4 (25 ng/mL) polarized WT BMDMs after 6 or 24 hours of exposure (n>2/group) [a portion of the data were also presented in (Puchalska et al., 2018)]. 10 mM [U-¹³C₆]glucose labeling of **(B)** citrate, **(C)** glutamate, and **(D)** malate in unpolarized (Control), LPS (25 ng/mL) or IL-4 (25 ng/mL) polarized WT BMDM after 24 hours of exposure (n>5/group). Tandem mass spectra of **(E)** UDP-GlcNAc (m/z precursor = 606.0743) and **(F)** itaconate (m/z precursor = 129.0193) standards and metabolites eluting at the same retention time as UDP-GlcNAc (m/z precursor = 606.0743) and itaconate (m/z precursor = 129.0193) in LPS extracts obtained from the WT BMDMs after 24 hours of exposure. **(G)** Leloir pathway converged with hexosamine biosynthetic pathway (HBP) illustrating possible interconversion between UDP-GlcNAc and UDP-GalNAc with the aid of GALT and/or GALE enzymes. P, phosphate; UGP2, UDP-glucose pyrophosphorylase; GALT, galactose-1-phosphate-uridyltransferase; GALE, UDP-galactose 4'-epimerase. Data expressed as the mean ± standard error of the mean (SEM). Significant differences determined by Multiple Student's *t* test with

Holm-Sidak correction when compared to Control. * $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; *****, $p < 0.00001$; \$, $p < 0.000001$, as indicated.

Figure S5 (related to Fig. 5). Itaconate and UDP-GlcNAc metabolism in macrophages lacking mitochondrial ketone metabolism. Transcript abundances of (A) cytosolic acetoacetyl-CoA synthase (*Aacs*) (part of the data utilized in (Puchalska et al., 2018)) or (B, C) genes which encode the enzymes that catalyzes the fate-committing HBP (*Gfpt1*) and itaconate biosynthesis (*Irg1*) reactions in unpolarized (Control), LPS (25 ng/mL) or IL-4 (25 ng/mL) polarized WT or SCOT-KO BMDMs with or without the addition on 1 mM AcAc after 24 hours of exposure ($n > 3$ /group). *Gfpt1* encodes the glutamine:fructose-6-phosphate-aminotransferase enzyme (GFAT) whereas *Irg1* encodes cis-aconitate decarboxylase (CAD). (D, E) Total pools of UDP-GlcNAc (or UDP-GalNAc), and itaconate normalized to total amount of protein [mg] in unpolarized, LPS or IL-4-polarized WT and SCOT-KO BMDMs with or without the addition on 1 mM AcAc during 24 hours of exposure ($n > 3$ /group). Competition between 10 mM [$U-^{13}C_6$]glucose derived labeling and 1 mM unlabeled AcAc of (F) itaconate or (G) UDP-GlcNAc in (F) IL-4 or (G) LPS-polarized WT or SCOT-KO BMDM after 24 hours of exposure ($n = 4$ /group; part of the BMDM WT data utilized from Panel 5B, 5C). Significant differences determined by Multiple Student's *t* test with Holm-Sidak correction when compared to M0 (control unpolarized macrophages) or one-way ANOVA. Data expressed as the mean \pm standard error of the mean (SEM). * $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; *****, $p < 0.00001$, as indicated.


Figure S6 (related to Fig. 6). Influence of exogenous itaconate on control unpolarized, LPS- and IL-4-polarized macrophages. (A) 10 mM [$U-^{13}C_6$]glucose derived labeling of itaconate in


presence or absence of 0.25 mM of exogenous unlabeled itaconate in unpolarized WT BMDM after 24 hours of exposure (n=4/group). 10 mM [U-¹³C₆]glucose derived labeling of **(B)** UDP-GlcNAc, **(C)** malate, and **(D)** lactate in LPS or IL-4 WT BMDM in presence or not of 0.25 mM of exogenous unlabeled itaconate after 24 hours of exposure (n=4/group). Significant differences determined by Multiple Student's t-test with Holm-Sidak correction when compared to M0 (unpolarized control macrophages) or one-way ANOVA. Data expressed as the mean ± standard error of the mean (SEM). * $p < 0.05$; ***, $p < 0.001$; *****, $p < 0.00001$, as indicated.


A List of metabolites identified based on m/z and RT


Metabolite	m/z (negative mode)	Retention time (min)	ID method
Glucose	179.0561	2-4	Standard
β OHB	103.0401	6-10	Standard
Alanine	88.0404	3-5	Standard
Lactate	89.0244	5-10	Standard
Glutamate	146.0459	10-14	Standard
Aspartate	132.0302	10-14	Standard
Glycerol-1-phosphate	171.0064	30-35	Standard
Succinate	117.0193	30-35	Standard
α -ketoglutarate	145.0142	30-35	Standard
Malate	133.0142	30-35	Standard
Citrate	191.0197	45-48	Standard
UDP-GlcNAc	606.0743	30-35	Standard
Itaconate	129.0193	30-35	Standard
Glucosamine-6-phosphate	259.0384	35-40	Standard
Hexose-phosphate	259.0224	30-35	RT match to glycerol-1-phosphate
Sedoheptulose-7-phosphate	289.0330	30-35	RT match to glycerol-1-phosphate
Pentose-phosphate	229.0119	30-35	RT match to glycerol-1-phosphate
Phosphoglycerate	184.9857	45-48	RT match to citrate
GlcNAc-phosphate	300.0490	30-35	RT match to glycerol-1-phosphate
Glutamine	145.0619	10-14	RT match to glutamate


B $[^{13}\text{C}]$ Glucose labeling of PPP and glycolytic intermediates














TRANSPARENT METHODS

Animal models. All experiments were carried out on a C57BL/6N x C57BL/6J hybrid background mice. Mice were maintained on a standard low-fat chow diet (2016 Teklad global 16% protein rodent diet) and given autoclaved water ad libitum. Lights were off between 1900 and 0700 in a room maintained at 22°C. Primary macrophage cultures were obtained from 9- to 16-week old male and female C57BL/6N x C57BL/6J sub-strain hybrid mice carrying the *Oxct1*^{flox/flox} allele previously described (Cotter et al., 2013). This allele encodes SCOT and is functionally wild type with no obvious phenotype in carriers (Cotter et al., 2013). Germline ubiquitous SCOT-KO mice are fully lethal in the neonatal period. To generate adult whole-body SCOT knockout mice, *Oxct1*^{flox/flox} animals were crossed with the ubiquitously expressed *Cre/ESR1* fusion [B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J, stock number 004682, Jackson Laboratory], and 6-week old Cre-positive offspring and their Cre-negative littermate controls were subjected to a 17-day tamoxifen (Cayman Chemical) injection regimen at 20 mg/kg animal weight. These animals are designated as ‘SCOT-KO’ and ‘WT’, respectively. A two-week washout period after the final injection was allowed for pre-existing SCOT protein turnover (Schugar et al., 2014). Successful KO was confirmed via Western blot for SCOT protein in heart and skeletal muscle and via lack of [¹³C]AcAc oxidation in bone marrow-derived macrophages (BMDM). In all studies, cells isolated from a single animal were counted as a single replicate unless otherwise indicated. Genotyping primers are found in Table below.

Gene	Forward Primer 5'→3'	Reverse Primer 5'→3'
<i>Oxct1</i>	TGGCCAACCTGGATGATACCTGG	TCCATGGTGACCACCACTTTGG
<i>Aacs</i>	TTAGAGACAACAGCTGCTCCAGGT	CCACCAATGACTCCGAAAGAG GAA
<i>Gfpt1</i>	CAGAGACTGGAATACAGAGGA	CCTTTCTTCTTAATGAGCTGGA
<i>Irg1</i>	GCAACATGATGCTCAAGTCTG	TGCTCCTCCGAATGATACCA
<i>Rpl32</i>	CCTCTGGTGAAGCCCAAGATC	TCTGGGTTTCCGCCAGTTT

All experiments were conducted using protocols approved by Institutional Animal Care and Use Committees at Sanford Burnham Prebys Medical Discovery Institute at Lake Nona and the University of Minnesota.

Bone marrow- derived macrophage (BMDM) isolation and culture. Animals were sacrificed by cervical dislocation prior to harvest of the femurs and tibia of both legs. The marrow was flushed out using cold Ca^{2+} and Mg^{2+} -free Hank's buffered salt solution (HBSS) delivered through 3-mL syringes and 23- to 27-gauge needles, respectively. The pooled marrow from one animal was dispersed using a P1000 micropipette, and debris was allowed to settle before the suspension was transferred into fresh tubes and centrifuged. The resulting pellet was resuspended in BMDM differentiation media (RPMI (Sigma, includes 10 mM glucose) with 10% L929 conditioned media, 10% fetal bovine serum (FBS), 2 mM glutamine, 10 U/mL penicillin/streptomycin) and distributed into tissue culture plates at an average density of one animal into 100-cm² total surface area for growth. Fresh differentiation media was added two days after isolation. At day 4, exhausted media and non-adherent cells were aspirated from the plates, cells were washed with pre-warmed HBSS, and fresh media was added. After a second media change on day 6, mature macrophages were used on day 7 for labeling and treatment studies. L929 conditioned media was generated by culturing L929 cells to confluence over the course of 4-5 days in 10% FBS supplemented DMEM (50 mL per 175 cm² flask), after which the media was removed, filtered, and aliquoted for frozen storage. For labeling experiments, the number of cells per well was roughly similar after 7 days of treatment. Note that absolute quantitation is not critical for the measurements of relative label incorporation utilized for all ITUM experiments. However, for the absolute molar quantification of UDP-GlcNAc and itaconate, concentration was normalized to the protein concentration of the lysate.

Stable isotopic labeling. BMDMs were incubated in glucose- and serum-free DMEM containing 2 mM glutamine for 1 h prior to the introduction of ^{12}C -unlabeled or ^{13}C -labeled substrates (Cambridge Isotope Laboratories). In order to perform ITUM analysis, for each studied ^{13}C -labeled substrate penetration, a ^{12}C -labeled substrate counterpart sample was prepared in parallel. Uniformly labeled $[\text{U-}^{13}\text{C}_4]\text{AcAc}$ (1 mM) was added to DMEM containing 10 mM glucose and 2 mM glutamine. For experiments using exogenously added $[\text{U-}^{13}\text{C}_6]\text{glucose}$ (10 mM), glucose-free DMEM was used. Uniformly labeled $[\text{U-}^{13}\text{C}_4]\text{AcAc}$ was generated by a base-catalyzed hydrolysis of $[\text{1,2,3,4-}^{13}\text{C}_4]\text{ethylacetoacetate}$ (ethyl-AcAc): 8 mL of 1 M NaOH was added to 1 mL ethyl-AcAc while stirring at 60°C . After 30 min, the reaction was neutralized with 50% HCl to pH 8, and the concentration of AcAc was determined with a colorimetric enzyme-based total ketone body assay (Wako) prior to aliquoting and storage at -80°C . Because the reaction generates equimolar quantities of EtOH and AcAc and no further purification of AcAc was undertaken, ethanol was added to control experiments at a concentration equal to that of the highest amount of AcAc used. Labeling experiments were done for 6 h and/or 24 h, at which points the media was removed and cells were processed using the metabolite extraction method described below. To induce M1 (lipopolysaccharide (LPS)-polarized, Millipore) or M2 (IL-4-polarized, R&D Systems) BMDMs, respectively, were added to a final concentration of 25 ng/mL to the labeling media at the same time the media was introduced to the cells after their 1 h incubation in glucose- and serum-free DMEM. To M0 (unpolarized control macrophages with no LPS or IL-4 polarization), matching volumes and concentrations of vehicle were added with unlabeled or labeled substrates. As with polarized states, substrate treatments (AcAc/Octanoate/itaconate) were introduced simultaneously with the labeling media, macrophage activators and maintained for either 6 h or 24 h.

Metabolite extraction. Cells were extracted using previously described method (Chen et al., 2016) with modifications. Cells were washed twice with pre-warmed PBS and once with Milli-Q water. The tissue culture plate was then placed in a liquid nitrogen bath for 30 s to quench metabolism and initiate cell lysis. Cold MeOH (-20°C) was added at a ratio of 500 µL per 6-cm dish or single well of a 6-well plate, the cells were scraped up, transferred to 1.7 mL polypropylene microfuge tubes, and MeOH was evaporated using a Speed-Vac (Savant SPD 1010). Cells were extracted using cold (-20°C) 1000 µL of 2:2:1 MeOH:acetonitrile:H₂O. Therefore, all samples were extracted by three cycles of vortexing, freeze-thawing, and water bath sonication. The samples were then incubated at -20°C for 1 h followed by a 10 min spin at maximum speed to remove proteins from the solvent, which was then transferred to fresh tubes and evaporated off in the speed-vac. The dried metabolite pellet was reconstituted in 40 µL (cells) in 1:1 acetonitrile:H₂O with the aid of vortexing and sonication, and incubated at 4°C for 1 h. Samples were then spun down and the supernatant was analyzed by LC/MS.

LC/MS analysis. Liquid chromatography was performed on a Dionex Ultimate 3000 RSLC using either a Phenomenex Luna NH₂ column (100 mm x 1 mm, 3 µm particle size) for untargeted metabolomics surveys or a Waters Acquity BEH Amide column (100 mm x 1 mm, 1.7 µm particle size) for targeted quantification of UDP-GlcNAc and itaconate. Both columns were used in hydrophilic interaction liquid chromatography (HILIC) mode, with the following mobile phase compositions: A = 95% H₂O, 5% ACN, 10 mM NH₄OAc/ NH₄OH, pH 9.5; B = 95% ACN, 5% H₂O, 10 mM NH₄OAc/ NH₄OH, pH 9.5. Unless otherwise stated, the extracts were usually separated on Luna NH₂ column using binary gradient 75-0% B for 45 min, then 0% B for 12 min, and 75%B for 13 min at 50 µL/min. Column temperature was maintained at 30°C, and injection volume was 4 µL. The BEH amide column was used for targeted quantification of UDP-GlcNAc

and itaconate with isocratic elution of 40% B at 80 $\mu\text{L}/\text{min}$, temperature at 30°C , and injection volume 4 μL . UDP-GlcNAc and itaconate quantifications were performed using external calibration curves. A range of standard calibration curves were generated depending on the targeted amount of the UDP-GlcNAc and itaconate in the sample. Due to the extended dynamic range of itaconate, 8 nM- 1000 nM and 10 μM -300 μM calibration curves were used. For the UDP-GlcNAc the molar concentration was calculated based on 8 nM- 1000 nM calibration curve. The molar concentration of itaconate and UDP-GlcNAc was normalized to the total protein amount from co- cultured macrophages wells ($n=4/\text{group}$) quantified by standard BCA protein assay (BCA protein assay kit, Thermo Scientific) protocol performed according to the manufacture specification. Mass spectrometry (MS) was performed on a Thermo Q Exactive Plus with heated ESI source. The MS was operated in negative mode. MS resolution was set to 70,000 and the AGC target to $3e^6$ ions with a maximum injection time of 200 ms. The mass scan for extract analysis was 68-1020 m/z , and UDP-GlcNAc and itaconate quantifications was 100-620 m/z , respectively. In targeted analysis, full scan mode was used with the addition of inclusion list of the ions of interests. To identify itaconate and UDP-GlcNAc, the Parallel Reaction Monitoring mode with inclusion list of ions was used. The resolution was set to 35,000, AGC target to $2e^5$ ions with a maximum injection time of 100 ms, isolation width 2.0 m/z , and fixed normalized collision energy 35 (arbitrary unit). Common ESI parameters were: auxiliary gas 10, sweep gas 1, spray voltage -3 kV, capillary temperature 275°C , S-lens RF 50, and auxiliary gas temperature 150°C . The sheath gas flow varied and for extract analysis was set to 35 (arbitrary unit), while for UDP-GlcNAc and itaconate quantifications was 45.

Identification of metabolites detected in LC/MS. The identity of a subset of metabolites was confirmed by matching the retention time of standard compounds run using identical

chromatographic separation conditions (**Fig. S1A**), or with the aid of PIUMet analysis (Pirhaji et al., 2016). For PIUMet analysis the files containing dysregulated m/z values, polarization modes, and $-\log$ of p values were uploaded for the analysis. To confirm the identification of UDP-GlcNAc (m/z 606.0743) in macrophage extracts, we compared the tandem mass spectrum and retention times of metabolites in extracts with their corresponding standards (**Fig. S4E**). Furthermore, treatment of BMDMs with increasing concentrations of exogenous N-acetylglucosamine (GlcNAc) substrate that feeds the HBP substantially increased the signal corresponding to the final UDP-GlcNAc product (**Fig. 3A**). However, we also considered the isobaric metabolite UDP-galactosamine (UDP-GalNAc), which could not be definitively ruled out due to the co-elution on chromatographic run together with UDP-GlcNAc (**Fig. S4G**). Confirmation of itaconate identification in the extracts was performed by matching retention times, and tandem mass spectrum of itaconate precursor with internal standard (**Fig. S4F**).

LC/MS data processing. Data from untargeted labeling profiling experiments (.RAW files) were converted to the mzXML format using MSConvert with the vendor peak-picking option selected, and processed using X¹³CMS R package as described previously (Cotter et al., 2014; Huang et al., 2014; Mahieu et al., 2016a; Mahieu et al., 2016b). For X¹³CMS, the data was processed using R studio where the XCMS (v. 1.40) package was used to pick chromatographic (method = 'centWave', ppm = 2.5 or 5, peakwidth = c(20, 180)) peaks and alignment retention time (bw=10, mzwid=0.015, retention time correction method = 'obiwarp') across samples within an experiment. X¹³CMS (v.1.4) was used on the output to extract isotopologue groups. The parameters used for X¹³CMS are RTwindow = 10, ppm = 5, noiseCutoff = 10000, intChoice = "intb", alpha = 0.05 within getIsoLabelReport(). Targeted experiments quantifying UDP-GlcNAc,

and itaconate were processed with Quan Browser (Thermo) using the Genesis peak detection and built-in integration algorithm.

Gene expression analysis. RNA was purified from cell extracts using the RNeasy Mini Kit (Qiagen) following the manufacturer's guidelines. Reverse transcripts were generated using SuperScript II (Invitrogen), while real-time reverse-transcription polymerase chain reaction (RT-PCR) was performed using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad) on the CFX384 Real-Time System (Bio-Rad). Transcripts were quantified using the $2^{-\Delta\Delta C_t}$ method, with *Rpl32* as an internal reference. Primer sequences are listed on page 11 of Supplemental Information.

Immunoblotting. Protein extracts were collected from 6-well macrophage cultures by scraping in protein lysis buffer (PLB) containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100 at pH 7.5 and supplemented with protease inhibitor cocktail (complete mini EDTA-free, Roche), phosphatase inhibitor cocktail (Sigma). Immunoblot analysis was performed as described previously (Wentz et al., 2010). Protein targets of interest were probed with the monoclonal mouse anti-O-GlcNAc (Cell Signaling; 1:5000) primary antibody. Secondary antibody was conjugated to horseradish peroxidase, anti-mouse IgG (Cell Signaling; 1:7000 for O-GlcNAc). Target was normalized to actin, which was probed with a polyclonal rabbit anti-actin (Sigma; varying dilutions) and goat anti-rabbit IgG-HRP (Southern Biotech). Band intensities were measured densitometrically using Quantity One software (Bio-Rad).

Statistics. Data were plotted and statistical analysis was performed on Prism (GraphPad) v7.0. Numbers of observations, assessments of normal distributions, and statistical tests applied are provided in the Figure Legends.

Data and software availability. All data obtained from X13CMS analysis is available in Supplementary Tables of this manuscript. Most of utilized software platforms used in this manuscript have free open source licenses. MSConvert free open source (<http://proteowizard.sourceforge.net/tools.shtml>); R studio (Ver 1.0.153) free open source license (<https://www.rstudio.com/products/rstudio/download/>); R package free open source (<http://r-pkgs.had.co.nz/>); X13CMS (v.1.4) package free open source license (<http://pattilab.wustl.edu/software/x13cms/x13cms.php>); PIUMet (<http://fraenkel-nsf.csbi.mit.edu/PIUMet/>);

Supplemental References

Chen, Y.J., Mahieu, N.G., Huang, X., Singh, M., Crawford, P.A., Johnson, S.L., Gross, R.W., Schaefer, J., and Patti, G.J. (2016). Lactate metabolism is associated with mammalian mitochondria. *Nat. Chem. Biol.* *12*, 937-943.

Cotter, D.G., Ercal, B., Huang, X., Leid, J.M., d'Avignon, D.A., Graham, M.J., Dietzen, D.J., Brunt, E.M., Patti, G.J., and Crawford, P.A. (2014). Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. *J. Clin. Invest.* *124*, 5175-5190.

Cotter, D.G., Schugar, R.C., Wentz, A.E., d'Avignon, D.A., and Crawford, P.A. (2013). Successful adaptation to ketosis by mice with tissue-specific deficiency of ketone body oxidation. *Am. J. Physiol. Endocrinol. Metab.* *304*, E363-74.

Huang, X., Chen, Y.J., Cho, K., Nikolskiy, I., Crawford, P.A., and Patti, G.J. (2014). X13CMS: global tracking of isotopic labels in untargeted metabolomics. *Anal. Chem.* *86*, 1632-1639.

Mahieu, N.G., Spalding, J.L., and Patti, G.J. (2016a). Warpgroup: increased precision of metabolomic data processing by consensus integration bound analysis. *Bioinformatics* *32*, 268-275.

Mahieu, N.G., Genenbacher, J.L., and Patti, G.J. (2016b). A roadmap for the XCMS family of software solutions in metabolomics. *Current Opinion in Chemical Biology* *30*, 87-93.

Pirhaji, L., Milani, P., Leidl, M., Curran, T., Avila-Pacheco, J., Clish, C.B., White, F.M., Saghatelian, A., and Fraenkel, E. (2016). Revealing disease-associated pathways by network integration of untargeted metabolomics. *Nat. Methods* *13*, 770-776.

Puchalska, P., Martin, S.E., Huang, X., Lengfeld, J., Graham, M., Daniel, B., Nagy, L., Han, X., Patti, G., and Crawford, P.A. (2018). Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis. *Cell Metab.* doi.org/10.1016/j.cmet.2018.10.015

Schugar, R.C., Moll, A.R., André d'Avignon, D., Weinheimer, C.J., Kovacs, A., and Crawford, P.A. (2014). Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. *Molecular Metabolism* 3, 754-769.

Wentz, A.E., d'Avignon, D.A., Weber, M.L., Cotter, D.G., Doherty, J.M., Kerns, R., Nagarajan, R., Reddy, N., Sambandam, N., and Crawford, P.A. (2010). Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. *J. Biol. Chem.* 285, 24447-24456.